RNPC3 and pulmonary fibrosis: Most organ system involvement and laboratory findings are primarily associated with SSc-related ANA, rather than the disease subsets.29 Pulmonary fibrosis (84%, P < 0·01 vs. total patients) and decreased %VC (44%, P < 0·05 vs. total patients) were most common in patients with anti-topo I and most infrequent in patients with ACA (7%, P < 0·01 and 4%, P < 0·05 vs. total patients, respectively, Table 1), as previously shown.27 Decreased %DLco was commonly seen in patients with SSc, except for patients with anti-Th/To (29%) or anti-U3 RNP (20%).